RA
CABA icon

Rise Advisors’s Cabaletta Bio CABA Stock Holding History

Rise Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,083
Closed -$2.53K – 301
2025
Q3 		$2.53K Hold
1,083
– – ﹤0.01% 1174
2025
Q2 		$1.65K Buy
+1,083
New +$1.69K ﹤0.01% 1213

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rise Advisors's CABA Position: Q4 2025 in Review

Rise Advisors sold out of Cabaletta Bio (CABA) in Q4 2025, closing a stake of 1,083 shares — an estimated $2.53K sold.

Rise Advisors first reported a position in CABA in Q2 2025 and held it in 2 quarters. The position peaked at $2.53K in Q3 2025. 95 funds tracked by Wall St. Rank hold CABA as of Q4 2025.

  • Rise Advisors reported no remaining Cabaletta Bio position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 1,083 Cabaletta Bio shares in Q4 2025, an estimated $2.53K.
  • Rise Advisors first reported a position in Cabaletta Bio in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Cabaletta Bio position peaked at $2.53K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.